Neil Stahl, EVP Research and Development at REGENERON PHARMACEUTICALS, INC. (REGN), sold 35,247 shares at $401.46 ($14.1M) on 2020-02-13, disclosed to the SEC on 2020-02-14.
Open-market sale of $14.1M REGN by EVP Research and Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $402.34 | 14,722 | $5.9M | 41.9% |
| 2 | $399.80 | 4,302 | $1.7M | 12.2% |
| 3 | $399.80 | 4,302 | $1.7M | 12.2% |
| 4 | $400.54 | 2,608 | $1.0M | 7.4% |
| 5 | $400.54 | 2,608 | $1.0M | 7.4% |
| 6 | $401.46 | 2,058 |
| $826K |
| 5.8% |
| 7 | $401.46 | 2,058 | $826K | 5.8% |
| 8 | $402.35 | 1,279 | $515K | 3.6% |
| 9 | $402.35 | 1,279 | $515K | 3.6% |
| 10 | $406.44 | 31 | $13K | 0.1% |
| Total | $401.36 avg | 35,247 | $14.1M | 100% |
| Filing → |
| REGN | SELL | 2023-08-23 | $19.6M | — | Filing → |
| REGN | SELL | 2022-08-08 | $28.4M | — | Filing → |
| REGN | SELL | 2021-05-18 | $18.2M | — | Filing → |